The article discusses a study which investigated the effects of cannabidiol in the treatment of patients with Parkinson's disease. Topics covered include the absence of statistically significant differences in unified Parkinson's disease rating scale scores and plasma brain-derived neurotrophic factor levels, and the possible effect of cannabidiol in improving quality of life measures in Parkinson's disease patients with no psychiatric comorbidities.